Bousquet et al (2007) showed that baseline total IgE (≥76 IU/mL) was the only predictor of omalizumab's efficacy (asthma exacerbation, AQLQ, physician's overall assessment) in the INNOVATE study.14 Here, IGHE is linked to asthma.